EUVIMEDEUVIMED entdecken
Crossref

Barriers to anti‐TNFalpha prescription among Italian physicians managing inflammatory bowel disease

Cristina Bezzio, Nicola Imperatore, Alessandro Armuzzi, Fernando Rizzello, Gianpiero Manes, Fabrizio Bossa, Emma Calabrese, Flavio Caprioli, Marco Daperno, Filippo Mocciaro, Ambrogio Orlando, Claudio Papi und 2 weitere

GastroHep · 2019

DOI: 10.1002/ygh2.331 ↗

Kurz gefasst

Fachartikel in der Zeitschrift GastroHep, 2019. Verfasst von Cristina Bezzio und 13 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Merck Sharp and Dohme.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Italian physicians managing IBD patients seem to prescribe anti-TNFalpha agents less frequently than physicians in other countries.

Aims

To investigate reasons and situations that limit the use of these medications.

Methods

A questionnaire was distributed to 600 physicians attending IG-IBD events.

Results

Two hundred eighty physicians (46.7%) completed the questionnaire. Most physicians (76.2%) prescribed anti-TNFalpha every time one was needed, however, 12.6% were limited by budget, 8.1% lacked confidence, 2.2% lacked permission and 0.9% chose not to prescribe them. The limitations in using anti-TNFalpha were: fear of side effects (39.1%), costs (38.2%), administrative/bureaucratic limitations (8.0%) and lack of staff (6.2%). The main feared side effects include: opportunistic infection (45.7%), neoplasms (25.4%), allergic reactions (12.5%), reactivation of tuberculosis (7.3%) and onset of autoimmune disease (7.3%). Physicians younger than 45 years of age and with less than 15 years of clinical experience were more likely to prescribe anti-TNFalpha than older physicians (70.8% vs 57.1%; P = 0.022) than more experienced physicians (71.2% vs 58.9%; P = 0.033).

Conclusions

The apparent underuse of anti-TNFalpha in Italy can be attributed mainly to physicians’ fears of side effects, concerns about costs and scarce familiarity with these drugs. Addressing these barriers may lead to an improvement in the quality of assistance to IBD patients.

Förderung

  • Merck Sharp and Dohme

Zitieren

APA

Bezzio, C., Imperatore, N., Armuzzi, A., Rizzello, F., Manes, G., Bossa, F., Calabrese, E., Caprioli, F., Daperno, M., Mocciaro, F., Orlando, A., Papi, C., Rispo, A., & Saibeni, S. (2019). Barriers to anti‐TNFalpha prescription among Italian physicians managing inflammatory bowel disease. GastroHep. https://doi.org/10.1002/ygh2.331

Vancouver

Bezzio C, Imperatore N, Armuzzi A, Rizzello F, Manes G, Bossa F, et al. Barriers to anti‐TNFalpha prescription among Italian physicians managing inflammatory bowel disease. GastroHep. 2019. doi:10.1002/ygh2.331

BibTeX
@article{Bezzio2019,
  author = {Bezzio, Cristina and Imperatore, Nicola and Armuzzi, Alessandro and Rizzello, Fernando and Manes, Gianpiero and Bossa, Fabrizio and Calabrese, Emma and Caprioli, Flavio and Daperno, Marco and Mocciaro, Filippo and Orlando, Ambrogio and Papi, Claudio and Rispo, Antonio and Saibeni, Simone},
  title = {Barriers to anti‐TNFalpha prescription among Italian physicians managing inflammatory bowel disease},
  journal = {GastroHep},
  year = {2019},
  doi = {10.1002/ygh2.331}
}
Kostenlos starten →